Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890· University Medical Center Groningen· Source
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
NCT07294170· argenx· Source
Active, not recruiting
A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar
NCT07160816· Novo Nordisk A/S· Source
Active, not recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542· Phase 3· Incyte Corporation· Source
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301· Phase 2/3· Eikon Therapeutics· Source
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
2023-507539-40-00· Phase 2· NMD Pharma A/S· Source
Recruiting
Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )
NCT07368582· Associazione Italiana Ematologia Oncologia Pediatrica· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)
NCT05974462· Phase 3· University Hospital, Antwerp· Source
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
NCT06414954· Phase 2· NMD Pharma A/S· Source
Recruiting
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
2023-505775-70-00· Phase 2· European Myeloma Network B.V.· Source
Recruiting
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
NCT06189833· Phase 2· European Myeloma Network B.V.· Source
Recruiting
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672· Phase 3· Italfarmaco· Source
Recruiting
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study
2023-506662-31-00· Phase 2· Fondazione GONO G.I.· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma
2023-503288-40-00· Phase 3· Amgen Inc.· Source
Recruiting
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
NCT05869279· Phase 1/2· Fondazione Matilde Tettamanti Menotti De Marchi Onlus· Source
Active, not recruiting
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134· Phase 2· Bristol-Myers Squibb· Source
Active, not recruiting
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510· Phase 3· OncoC4, Inc.· Source
Recruiting
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
NCT05907057· Phase 3· Servier Affaires Médicales· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906· Phase 3· Bayer· Source
Active, not recruiting
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
NCT05526755· Phase 2· AstraZeneca· Source
Active, not recruiting
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
NCT05491200· Phase 4· Research Maatschap Cardiologen Rotterdam Zuid· Source
Active, not recruiting
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
NCT04613921· European Foundation for Study of Chronic Liver Failure· Source
Active, not recruiting
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
NCT04604067· Phase 2· Swiss Cancer Institute· Source
Recruiting
Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure
NCT06884631· Centro Cardiologico Monzino· Source
Active, not recruiting
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)
2022-502354-14-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Active, not recruiting
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source
Active, not recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429· Phase 3· Madrigal Pharmaceuticals, Inc.· Source
Active, not recruiting
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592· Phase 3· Fondazione Michelangelo· Source
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· Phase 2/3· Celgene· Source
Enrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
NCT06041906· Prof. Valérie Mc Lin· Source
Active, not recruiting
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621· Phase 3· Eli Lilly and Company· Source
Recruiting
Arrhythmias Detection in a Real World Population
NCT02275637· Fondazione IRCCS Policlinico San Matteo di Pavia· Source
Active, not recruiting
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
NCT01761968· Phase 2· Italfarmaco· Source